The per-patient costs of HIV services in South Africa: Systematic review and application in the South African HIV Investment Case
The paper details the results of the first-ever systematic review of the average (or unit) costs of HIV interventions in South Africa, performed in 2018. We originally did this for the South African HIV Investment Case but have updated to more recent prices (2016/17) and added more interventions since then. It includes recent costs for ...
Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058
Our objective was to assess cost-effectiveness and costs of introducing PrEP in Germany.We calibrated a deterministic mathematical model to the human immunodeficiency virus (HIV)epidemic among MSM in Germany. PrEP was targeted to 30% of high-risk MSM. It was assumed that PrEP
reduces the risk of HIV infection by 85%. Costs were calculated from a ...
Delays in diagnosis of HIV and initiation of antiretroviral therapy (ART) for infants significantly increase early infant morbidity and mortality. By contrast, innovations in early infant HIV diagnostics and improvements in turnaround times could reduce infant morbidity and mortality.
The Health Economics and Epidemiology Research Office (HE2RO) of the University of the Witwatersrand seeks a dynamic, enthusiastic, and self-motivated quantitative senior researcher with experience in mathematical disease, cost, and/or health systems modelling to be part of our health economics and epidemiology research portfolios. Research in these portfolios focus on the impact, costs, cost-effectiveness, and ...
- HE2RO is not currently offering any courses. Please keep checking back on the website for updates
HE2RO has been awarded a new 5-year Co-operative Agreement from USAID. This new program, the HIV/AIDS Economics and Research Activity, called EVIDENCE will run...
HE2RO has been approved to be a HBNU site for the Fogarty Global Health Training Program. The program provides opportunities to generate a new...
HE2RO and BU are pleased to announce a new project focusing on differentiated models of HIV treatment delivery: AMBIT.